Celgene's Apremilast Looks Positive in Top-Line PsA Data
Celgene International Sàrl, the Boudry, Switzerland, subsidiary of Celgene Corp., reported positive top-line results for apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients with psoriatic arthritis (PsA) who had received an oral disease-modifying antirheumatic drug (DMARD) or biologic therapy or had failed on an anti-tumor necrosis factor (TNF) agent.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter